Producing High-Quality, Therapeutically Relevant NK Cells Using A Large-Scale Biomanufacturing Platform

The LEAP™ platform offered by BioCentriq provides early-stage biotech companies with novel cell therapy candidates an avenue to leverage proven expertise and assets to reach patients in record time. Sponsors who leverage LEAP™ minimize up-front investment in process development, reduce risk, accelerate timelines, and lower the cost of IND-enabling studies and clinical production.

Data demonstrating the efficacy of BioCentriq's LEAP-NK™ platform can be found in this poster. The results of the study displayed in the poster suggest that BioCentriq’s LEAP-NK™ platform utilizing propriety feeder cell lines can enhance expansion of NK cells >12,000 fold.